Suzhou Ribo Life Science

6938 · HKEX

Public Market Listing

6938HKEX

HKEX primary exchange listing

Live quotes, historical charts, and market capitalization for Suzhou Ribo Life Science are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(3 total)
3Total Assets
0Approved
1Phase 3 / Filed
2Phase 1–2 / Early
2Diseases
Quick filter:
Showing 3 of 3 assets
Target & Modality
Phase 3
PCSK9RNA / oligonucleotide
Atherosclerotic Cardiovascular Disease
Phase 2
APOC3RNA / oligonucleotide
Cardiovascular Disease / Dyslipidemia
Hypertriglyceridemia
Phase 1
PCSK9RNA / oligonucleotide
Atherosclerotic Cardiovascular Disease

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
October 2027 (1)
QLC7401Phase 3Primary Hypercholesterolemia or Mixed Hyperlipidemia
Est. primary completion 2027-10-07 · NCT07444086 · CT.gov ↗
What to watch
December 2027 (1)
QLC7401Phase 3Primary Hypercholesterolemia or Mixed Hyperlipidemia
Est. primary completion 2027-12 · NCT07441317 · CT.gov ↗
What to watch
2028 (1)
April 2028 (1)
QLC7401Phase 3Heterozygous Familial Hypercholesterolemia (HeFH)
Est. primary completion 2028-04 · NCT07450378 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (1)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-H1$14M——$13Mreport ↗

Annual history (2 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$20M$39M——report ↗

Suzhou Ribo Life Science reported revenue of $19.76M, up 197500.0% YoY and R&D spend of $38.97M, down 12.6% YoY for fiscal year 2024.

Figures only: this period's report disclosed no narrative text

View 1 more year
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2023-FY<$0.1M$45M——report ↗